In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Zogenix secures $30mm in cash from Cowen in exchange for royalties

Executive Summary

Zogenix Inc. has received $30mm in cash from Cowen Healthcare Royalty Partners II LP. The neurology drug company will repay the debt using a percentage of product sales and co-promotion and out-licensing revenues from its migraine and headache treatment Sumavel DosePro (which is partnered with Astellas in the US), and future drugs including chronic pain candidate Zohydro (hydrocodone; formerly ZX002), which is finishing up Phase III and could be filed for approved in early 2012. The transaction will expire on March 31, 2018.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies